First, in our cohort of 27 patients, we failed to show the impact of polymorphisms of OATP-related genes on paritaprevir concentrations and the development of hyperbilirubinemia (data not shown). The gene discussed is SLCO1A2; the disease is Hyperbilirubinemia.